Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Feb 12, 2025

SELL
$0.0 - $32.48 $0 - $266,530
-8,206 Closed
0 $0
Q4 2023

Feb 12, 2025

SELL
$12.63 - $24.47 $39,430 - $76,395
-3,122 Reduced 27.56%
8,206 $194 Million
Q3 2023

Feb 12, 2025

BUY
$10.86 - $17.62 $123,022 - $199,599
11,328 New
11,328 $169 Million

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Bit Capital Gmb H Portfolio

Follow Bit Capital Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bit Capital Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Bit Capital Gmb H with notifications on news.